ABIVAX Société Anonyme (NASDAQ:ABVX) Receives $38.67 Consensus Price Target from Brokerages

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have received a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $38.67.

Several equities analysts recently weighed in on ABVX shares. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Kennedy Capital Management LLC lifted its holdings in shares of ABIVAX Société Anonyme by 0.7% in the 4th quarter. Kennedy Capital Management LLC now owns 225,470 shares of the company’s stock worth $1,650,000 after purchasing an additional 1,656 shares during the last quarter. Bank of America Corp DE increased its position in shares of ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares during the period. GAMMA Investing LLC acquired a new position in shares of ABIVAX Société Anonyme during the 4th quarter valued at $29,000. R Squared Ltd acquired a new position in shares of ABIVAX Société Anonyme during the 4th quarter valued at $36,000. Finally, BNP Paribas Financial Markets increased its position in shares of ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the period. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Performance

Shares of NASDAQ:ABVX opened at $5.94 on Friday. ABIVAX Société Anonyme has a 52-week low of $5.50 and a 52-week high of $17.02. The stock’s fifty day simple moving average is $6.72 and its 200-day simple moving average is $8.70.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.